Whitehawk Therapeutics (WHWK) Non-Current Debt (2021)
Whitehawk Therapeutics (WHWK) reported Non-Current Debt of $5.8 million for Q4 2021, little changed quarter-over-quarter from $5.8 million in Q3 2021.
Whitehawk Therapeutics (WHWK) Non-Current Debt (2021) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 1 years of Non-Current Debt data on file, last reported at $5.8 million in Q4 2021.
- Non-Current Debt for Q4 2021 came in at $5.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $5.8 million (changed N/A YoY), and the FY2021 annual result was $5.8 million, changed N/A from the prior year.
- Non-Current Debt held at $5.8 million in Q4 2021 per WHWK's latest filing, from $5.8 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $5.8 million in Q3 2021 and troughed at $5.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.76 Mn |
| Dec 31, 2021 | 5.76 Mn |
| Sep 30, 2021 | 5.76 Mn |
| Sep 30, 2021 | 5.76 Mn |